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Introduction
The endosomal network plays a crucial role in the delivery of  integral membrane proteins (also referred 
to as cargo proteins) either to lysosomes for proteolysis, to the trans-Golgi network, or to the plasma mem-
brane. In recent years, the Wiskott-Aldrich syndrome protein and SCAR homolog (WASH) complex has 
emerged as one of  the key multiprotein complexes facilitating the endosomal sorting of  cargos (1–3), such 
as the EGFR (4), copper-transporting P-type ATPase ATP7A (5), and the β2-adrenoreceptor (6, 7). The 
WASH complex consists of  5 subunits, WASHC1 (WASH1), WASHC2 (FAM21), WASHC3 (CCDC53), 
WASHC4 (SWIP), and WASHC5 (Strumpellin or KIAA0196) and governs the destination of  cargos by 
activating the Arp2/3 complex (8, 9). Arp2/3 forms actin-enriched subdomains on the endosomal mem-
brane from where cargos are sorted and transported (10, 11).
Mutations in several components of  the WASH complex have been identified in developmental and 
neurological disorders: mutations in WASHC4 have been found in patients with nonsyndromic autosomal 
recessive intellectual disability (12), while defects in WASHC5 have been reported in patients with autoso-
mal dominant hereditary spastic paraplegia (13, 14) or Ritscher-Schinzel/3C syndrome (RSS) (15). Surpris-
ingly, our recent in vitro work also implicated a role for the WASH complex in the metabolism of  LDL cho-
lesterol (LDL-C). We found that WASHC1 deficiency impairs endosomal trafficking of  the LDL receptor 
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(LDLR), leading to LDLR accumulation in endosomes, reduced LDLR surface levels and impaired LDL 
uptake in mouse embryonic fibroblasts (MEFs) (16). Furthermore, we showed that hepatic destabilization 
of  the WASH-associated CCC (COMMD-CCDC22-CCDC93) complex increases plasma LDL-C levels in 
mice, dogs, and humans and accelerates atherosclerosis in mice (16, 17). These data strongly indicate the 
involvement of  the WASH complex in the regulation of  cholesterol homoeostasis. Accordingly, we report-
ed a patient with familial RSS presenting with hypercholesterolemia (16), beyond developmental malfor-
mation and intellectual disability. However, due to the clinical complexity of  RSS and because we assessed 
the plasma cholesterol levels from only 1 patient with RSS, the true contribution of  the WASH complex to 
cholesterol homeostasis at an organismal level has remained unclear. Furthermore, it has been shown that 
the endolysosomal system is essential for the proprotein convertase subtilisin-kexin type 9 (PCSK9) and 
inducible degrader of  LDLR (IDOL)-mediated LDLR degradation pathways (18–22), but the role of  the 
WASH-CCC axis in these 2 pathways is still unknown.
We, therefore generated liver-specific WASH-deficient mice to establish the role of  the WASH complex in 
the regulation of  whole-body cholesterol metabolism. We found that ablation of  the WASH complex leads to 
elevated plasma levels of  cholesterol in both LDL and HDL fractions. In addition, we observed that WASH is 
not only required for the cell surface expression of  the LDLR family members (i.e., LDLR and LDLR-related 
protein 1 [LRP1]), but also of  the scavenger receptor class B type I (SR-BI), the main receptor that mediates 
selective uptake of  cholesteryl esters (CEs) from HDL into hepatocytes. Kinetic studies showed that selective 
HDL-CE uptake was impaired in hepatic WASH-deficient mice. Finally, we found that the WASH com-
plex delays IDOL-mediated LDLR degradation but does not influence PCSK9-induced LDLR proteolysis. 
Intriguingly, hepatic Washc1 ablation sensitized LRP1 degradation by PCSK9 in vivo. Altogether, our results 
imply that, in addition to its role in developmental and neurological processes, the WASH complex is involved 
in hepatic uptake of  plasma LDL-C, HDL cholesterol (HDL-C), and IDOL-mediated LDLR degradation.
Results
Depletion of  Washc1 destabilizes the WASH complex and adversely affects the lysosomal architecture in hepatocytes. To 
decipher the role of  the hepatic WASH complex in cholesterol homeostasis, we generated a liver-specific 
Washc1-knockout model (Washc1ΔHep) by cross-breeding mice carrying floxed Washc1 alleles (Washc1fl/fl) (4) 
with transgenic mice expressing Cre recombinase in hepatocytes under the control of  the Albumin (Alb) gene 
promoter. Successful ablation of  hepatic WASHC1 was confirmed by immunoblotting (Figure 1, A and B). 
In line with previous findings in MEFs (4), hepatic WASHC1 deficiency strongly reduced the abundance 
of  all WASH components (Figure 1, A and B) without affecting the mRNA levels of  these subunits (Sup-
plemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.126462DS1), illustrating the importance of  WASHC1 in the formation of  a stable WASH complex 
in mouse liver. Washc1ΔHep mice were born at the expected Mendelian ratio (Supplemental Figure 1B) and 
showed no overt changes in body weight, liver weight, or general liver histology compared with littermate 
controls (from now on referred to as WT) (Supplemental Figure 1, C and D). WASH binds to many different 
multiprotein complexes, such as the CCC complex, retriever, and retromer, to coordinate the endosomal 
trafficking of  cargos (5, 9, 16, 23–26). Ablation of  the WASH complex did not have a large effect on the 
abundance of  any subunit of  these complexes (Supplemental Figure 1E).
In vitro studies have shown that WASH deficiency alters the morphology of  the endosomes and lyso-
somal structure (4, 8–10). We therefore examined the lysosomal structure by electron microscopy (EM) in 
liver sections of  WT and Washc1ΔHep mice. Hepatic ablation of  the WASH complex decreased the average 
size of  the lysosomes (Figure 1, C and D). In addition, we found that WASH deficiency induced lysosomal 
tubulation (Figure 1E). In WT hepatocytes, 4.4% (11 of  250 lysosomes) of  the lysosomes were tubulated, 
whereas in Washc1 ablated hepatocytes, the percentage of  tubulated lysosomes was increased to 14.8% 
(37 of  250 lysosomes). However, the loss of  hepatic WASH did not noticeably alter the morphology of  
other organelles such as Golgi, endoplasmic reticulum, or mitochondria. These results demonstrate that 
we successfully deleted Washc1 in mouse livers, which results in destabilization of  the WASH complex and 
changes in lysosomal architecture in mouse hepatocytes in vivo.
Loss of  hepatic WASH results in elevated plasma LDL and HDL-C levels. To determine the effect of  hepatic 
WASH deficiency on circulating lipids, we measured total plasma cholesterol (TC) and triglyceride (TG) 
levels in chow-fed WT and Washc1ΔHep mice. Hepatic inactivation of  the WASH complex increased TC 
without affecting TG levels (Figure 2A). Using targeted proteomics (17), we observed increased plasma 
3insight.jci.org   https://doi.org/10.1172/jci.insight.126462
R E S E A R C H  A R T I C L E
levels of  apolipoproteins ApoE and ApoB in Washc1ΔHep mice compared with WT mice (Figure 2B). In 
line with the increased ApoB levels, the cholesterol content of  the LDL fraction separated by fast protein 
liquid chromatography (FPLC) was increased (Figure 2, C and D). We also found the HDL fraction to be 
enriched with cholesterol and increased in size (Figure 2C). Although total plasma ApoA-I levels were not 
affected (Figure 2B) in Washc1ΔHep mice, we observed a shift of  ApoA-I toward earlier eluting FPLC frac-
tions (Figure 2E). These fractions also contain ApoE (Figure 2F). Altogether, the shift of  ApoA-I, ApoE, 
and HDL-C into earlier eluted FPLC fractions indicates that HDL particles in Washc1ΔHep mice are larger 
than in WT mice (27–29). An increase in TC, LDL-C, and larger HDL particles was also seen in female 
Washc1ΔHep mice (Supplemental Figure 2, A–C).
In contrast to humans, mice do not express cholesteryl ester transfer protein (CETP), which 
exchanges HDL-C esters for TG in very low-density lipoprotein (VLDL) and LDL (30). As a conse-
quence, mice carry plasma cholesterol mainly in HDL rather than in LDL (31). This modest plasma 
LDL-C increase in Washc1ΔHep mice is very similar as seen in mice heterozygous for an Ldlr-knockout 
allele (32). To further assess the effect of  hepatic Washc1 deletion on plasma LDL and HDL-C levels 
in mice with a more human-like lipoprotein profile, we injected both Washc1ΔHep and WT mice with an 
adenovirus-expressing human CETP (Ad-CETP). A similar hepatic level of  human CETP expression 
was observed in Washc1ΔHep and WT mice (Figure 3A). In agreement with previous studies (33, 34), 
ectopic expression of  CETP decreased TC levels in mice (Figure 3B) compared with mice not express-
ing CETP (Figure 2A), but the TC levels were significantly higher in CETP-expressing Washc1ΔHep mice 
compared with WT mice (Figure 3B). Hepatic expression of  human CETP resulted in the expected 
shift of  cholesterol from HDL toward LDL in both Washc1ΔHep and WT mice (Figure 3C). However, in 
Washc1ΔHep, the LDL-C, HDL-C, as well as the apolipoproteins ApoB, Apo-AI, and ApoE levels were 
increased compared with WT mice (Figure 3, C and D). CETP expression normalized the increased 
HDL particles in the Washc1ΔHep mice (Figure 2C) compared with Washc1ΔHep mice without CETP 
expression (Figure 3C), a phenomenon also seen in SR-B1–deficient mice upon CETP expression (34).
We found that hepatic Washc1 ablation did not affect hepatic cholesterol and TG contents, VLDL pro-
duction, and whole-body cholesterol synthesis rates (Supplemental Figure 3, A–D). Several liver X recep-
tor (LXR) targets, including genes involved in biliary cholesterol secretion and bile acid synthesis (Abcg5, 
Abcg8, and Cyp7a1) were decreased upon hepatic Washc1 depletion compared to WT livers (Supplemental 
Table 1), suggesting that LXR activation was decreased in Washc1ΔHep mice. However, these changes did not 
translate into aberrant biliary cholesterol and bile acid excretion nor in altered fecal neutral sterol and bile 
acid loss (Supplemental Figure 3, E–H). No significant differences in the mRNA levels of  the SREBP-2 
target genes, such as Ldlr and Hmgcr, were found (Supplemental Table 1).
These data indicate that the WASH complex in the liver plays an important role in the regulation 
of  plasma LDL-C and HDL-C levels, but does not have a prominent role in the control of  whole-body 
cholesterol turnover.
The WASH complex is required for normal expression of  LDLR and LRP1 at the cell surface. We have recently 
shown that WASH mediates endosomal recycling of  LDLR back to the cell surface in MEFs (16). There-
fore, we hypothesized that the increased LDL-C levels in Washc1ΔHep are due to reduced surface levels of  
LDLR caused by impaired LDLR recycling. To test this theory, cell surface levels of  LDLR were deter-
mined in primary hepatocytes using a biotinylation assay. We found that the levels of  LDLR were reduced 
in the plasma membranes of  WASH-deficient primary hepatocytes compared with WT cells (Figure 4, A 
and B). Previously, we showed that the WASH-associated CCC complex also facilities the trafficking of  
LRP1 to the plasma membrane of  primary hepatocytes (17). Consistent with this finding, we learned that 
WASH is also required for normal levels of  LRP1 at the cell surface (Figure 4, A and B). In addition to the 
surface levels, the total protein levels of  LDLR and LRP1 were also reduced in WASH-deficient primary 
hepatocytes (Figure 4, A and B). This is likely due to the impaired retrieval of  these receptors from the 
lysosomal proteolytic fate into the recycling pathway (4, 16, 23).
In mice, the role of  hepatic LRP1 in the clearance of  plasma cholesterol is redundant, as LDLR can 
compensate for LRP1 loss (35). To address the role of  WASH in LRP1-mediated plasma cholesterol uptake, 
we expressed a human gain-of-function variant of  PCSK9 (D377Y) in mouse livers using an adeno-associat-
ed virus (AAV) expression system to ablate hepatic LDLR levels (17, 36). In both Washc1ΔHep and WT mice, 
the expression of  PCSK9-D377Y blunted hepatic LDLR levels (Figure 4C). Remarkably, although PCSK9 
does not have an effect on hepatic LRP1 degradation in WT mice (17, 37, 38), we found that in the absence 
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of  the WASH complex, LRP1 levels were significantly decreased upon PCSK9 overexpression in mouse liv-
ers (Figure 4, C and D, and Supplemental Figure 4). As shown in Figure 4E, this modest decrease in LRP1 
levels was not caused by a decrease in Lrp1 mRNA levels.
We found that hepatic Washc1 depletion exacerbated hypercholesterolemia in PCSK9-induced hepat-
ic LDLR deficiency (Figure 4F). Consistent with the increased plasma chylomicron remnant/VLDL 
and LDL lipoprotein fractions (Figure 4G), plasma ApoB48 and ApoB100 levels were elevated in mice 
deficient for hepatic WASH and LDLR compared with mice lacking only hepatic LDLR (Figure 4, H 
and I). Hepatic expression of  PCSK9 also increased ApoA-I levels in this model, while HDL-C levels 
were unchanged (Figure 4H). Hepatic WASH/LDLR deficiency mimics the plasma lipid phenotype in 
hepatic LRP1-deficient mice in an Ldlr-knockout background (35), suggesting that the WASH complex is 
also required for hepatic LRP1-mediated cholesterol uptake in vivo. These data demonstrate that hepatic 
Figure 1. WASHC1 deficiency destabilizes the WASH complex and perturbs lysosomal structures in primary hepatocytes. (A) Protein expression of the 
WASH complex components in liver homogenates of WT and Washc1ΔHep mice as determined by immunoblotting. (B) Quantification of immunoblot results 
depicted in A. (C) EM images of WT and Washc1ΔHep livers. BC, bile canaliculus, ER, endoplasmic reticulum; LD, lipid droplet; Lys, lysosome; Mito, mito-
chondrion. (D) Quantification of WT (n = 57) and Washc1ΔHep (n = 63) lysosomal area in liver sections. (E) EM image depicting aberrant lysosomal structure 
in Washc1ΔHep hepatocyte. Inset shows magnified area with tubulated lysosomes. For visualization of lysosomal tubulation, lysosomal perimeters were 
selected using the Lasso tool in Adobe Photoshop and color was added to the selected organelles. Data are presented as the mean ± SEM, *P < 0.05,  
**P < 0.01, ***P < 0.001 as determined by Student’s t test.
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depletion of  WASH impairs the functioning of  both LDLR and LRP1 in the uptake of  plasma cholesterol 
leading to hypercholesterolemia and, likely, sensitizes LRP1 for PCSK9-induced degradation.
HDL-C uptake is impaired in hepatic WASH-deficient mice due to reduced surface SR-BI levels. In addition to 
accumulation of  cholesterol in LDL, we also found plasma levels of  HDL-C to be increased in Washc1ΔHep 
mice (Figure 2C). In mice, HDL-C is mainly cleared by SR-BI, a membrane receptor that selectively takes 
up CE from HDL rather than internalizing the holoparticle (39). To assess whether the accumulation of  
plasma HDL-C in Washc1ΔHep mice is due to impaired endosomal trafficking of  SR-BI to the plasma mem-
brane, we applied a biotinylation assay to examine the cell surface levels of  SR-BI in primary hepatocytes. 
We found the cell surface abundance of  SR-BI to be markedly decreased in WASH-deficient hepatocytes 
compared with WT cells (Figure 5A). It has been shown that the enzyme hepatic lipase (HL) increases 
Figure 2. Loss of hepatic WASHC1 results in increased plasma LDL-C and HDL-C. (A) Total plasma cholesterol and 
TG levels in WT and Washc1ΔHep male mice (n = 5–7). (B) Plasma apolipoprotein levels in WT and Washc1ΔHep mice 
measured by targeted proteomics, indicated by fold change vs WT controls (n = 8). (C) Cholesterol levels in FPLC frac-
tionated plasma pools of the experimental groups of mice. (D–F) Apolipoproteins in pooled FPLC fractionated plasma 
of WT and Washc1ΔHep mice depicted in C determined by targeted proteomics, indicated as percentage relative to the 
total apolipoprotein levels in these fractions (n = 5–7). BDL, below detection limit. Data are presented as the mean ± 
SEM, *P < 0.05, **P < 0.01, ***P < 0.001 as determined by Student’s t test.
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hepatic HDL-CE uptake (40–43). However, we did not find any difference in plasma HL levels as measured 
by targeted proteomics (Figure 5B), which makes it unlikely that HL contributes to the increased plasma 
HDL-C levels in hepatic WASH-deficient mice.
To establish the consequences of the reduced hepatocyte SR-BI surface levels in hepatic WASH-deficient 
mice in more detail, we compared the uptake of HDL-associated CE and HDL holoparticles between WT and 
Washc1ΔHep mice upon injecting these mice with HDL particles containing 3H-labeled CE as well as 125I-labeled 
proteins. Selective HDL-C uptake was calculated from the difference in the uptake of both tracers. Plasma 
decay of radioiodine reflecting holoparticle HDL was not different between WT and Washc1ΔHep mice (Figure 
5C). However, 3H-HDL-CE clearance was delayed upon hepatic WASH inactivation (Figure 5C). From the 
decay curves, we calculated plasma fractional catabolic rates and observed that HDL-CE clearance in hepatic 
WASH-deficient mice was significantly reduced compared with WT mice, whereas holoparticle uptake was 
not changed (Figure 5D). As a consequence, the difference reflecting selective HDL-CE uptake by Washc1ΔHep 
livers was significantly decreased compared with WT livers (Figure 5E). The kidney is the main organ for the 
catabolism of small, poorly lipidated ApoA-I molecules and does not express SR-BI (39, 44). In line with previ-
ous studies (45), the renal uptake rate of HDL-CE was much lower than with hepatic HDL-CE uptake, and no 
differences were observed between WT and Washc1ΔHep mice (data not shown). Overall, these results indicate 
that the hepatic uptake of HDL-CE is impaired in Washc1ΔHep mice likely due to reduced expression of SR-BI 
at the plasma membrane of hepatocytes.
Results from previous and current studies imply that the WASH and CCC complex act in concert to regu-
late plasma lipid levels. To validate this at an organismal level, we inactivated both protein complexes in mouse 
livers by cross-breeding Washc1ΔHep mice with mice carrying Commd1 floxed alleles (Washc1/Commd1ΔHep) (16, 
46) (Figure 6A). Hepatic ablation of both complexes did not further increase total plasma cholesterol lev-
els when compared with hepatic Washc1 and Commd1 single-knockout mice (Figure 6B). In addition, hepatic 
ablation of both complexes also resulted in increased plasma LDL-C (Figure 6, C and D) and larger HDL-C 
particles (Figure 6, C and D), similar to that was seen in single-knockout models (Figure 2 and refs. 16, 17). 
Figure 3. Hepatic WASHC1 deficiency results in increased plasma LDL-C and HDL-C in mice expressing CETP. (A) Hepatic CETP mRNA expression after 
Ad-CETP administration. (B) Total plasma cholesterol levels 3 days after Ad-CETP administration in male WT and Washc1ΔHep mice. (C) Cholesterol levels 
of FPLC fractionated pooled plasma of the experimental groups of mice after Ad-CETP administration (n = 5–6). (D) Apolipoproteins in pooled FPLC frac-
tionated plasma of WT + CETP and Washc1ΔHep + CETP mice depicted in C determined by targeted proteomics, indicated as percentage relative to the total 
apolipoprotein levels in these fractions. Data are presented as the mean ± SEM, ***P < 0.001 as determined by Student’s t test.
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Figure 4. The WASH complex is required for normal cell surface expression of LDLR and LRP1. (A) Representative immunoblot of whole-cell and cell-sur-
face protein levels of LDLR and LRP1 in WT and Washc1–/– primary hepatocytes. (B) Quantification of total and cell surface levels of LDLR and LRP1 (n = 4). (C) 
Representative immunoblot of hepatic LDLR and LRP1 3 weeks after AAV-PCSK9-D377Y administration. (D) Quantification of hepatic LRP1 protein levels in 
male WT and Washc1ΔHep mice 3 weeks after AAV-PCSK9-D377Y administration as determined by immunoblotting (n = 6–7). (E) Hepatic Lrp1 mRNA expression 
in the experimental groups of mice depicted in D. (F) Total plasma cholesterol levels in male WT and Washc1ΔHep mice before and 3 weeks after AAV-PCSK9-
D377Y administration (n = 6–7). (G) TC levels of FPLC fractionated pooled plasma of WT and Washc1ΔHep 3 weeks after AAV-PCSK9-D377Y administration. CR, 
chylomicron remnants (n = 6–7). (H) Relative plasma apolipoprotein levels in WT and Washc1ΔHep mice after AAV-PCSK9-D377Y administration as measured by 
targeted proteomics. (I) Coomassie blue staining of ApoB100 and ApoB48 in WT and Washc1ΔHep plasma before and after AAV-PCSK9-D377Y administration. 
Data are presented as the mean ± SEM, **P < 0.01, ***P < 0.001 as determined by Student’s t test.
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Furthermore, targeted proteomics analysis of FPLC fractions showed a leftward shift of ApoA-I and ApoE 
(Figure 6E), confirming that the HDL particles are also larger in Washc1/Commd1ΔHep mice (Figure 2, D–F). 
These in vivo data support the notion that the WASH and CCC complexes act together to form a crucial sort-
ing pathway that is required to maintain normal plasma cholesterol levels.
IDOL- but not PCSK9-mediated LDLR degradation is exacerbated by WASH deficiency. The endocytic 
system is crucial for the LDLR degradation pathways mediated by either PCSK9 or IDOL, but the 
contribution of  the WASH-CCC axis in these degradation pathways has yet to be defined. To this 
end, we assessed the effect of  WASH deficiency on PCSK9- and IDOL-mediated LDLR degradation. 
WT and WASHC1-deficient MEFs (ref. 16 and Figure 7A) were incubated with recombinant human 
PCSK9 (2.5 μg/ml), and whole-cell extracts were harvested at different time points (Figure 7B). Immu-
noblots showed that PCSK9 decreased total LDLR levels in WT and WASHC1-deficient cells, but loss 
of  WASHC1 did not affect the degradation kinetics of  LDLR by PCSK9 (Figure 7, B and C).
Next, we incubated WT and WASHC1-deficient MEFs with the LXR agonist T0901317 (1 μM T09) 
to induce IDOL expression (47). Cells were collected at different intervals over an 8-hour period, and total 
Figure 5. Hepatic uptake of HDL-C is impaired by reduced surface levels of SR-BI in hepatic WASH-deficient mice.  
(A) Immunoblot of whole-cell and cell-surface SR-BI levels in WT and Washc1–/– primary hepatocytes. (B) Plasma hepatic 
lipase levels of male WT and Washc1ΔHep mice as determined by targeted proteomics (n = 6). (C) HDL protein (125I) and 
HDL-C (3H) plasma decay in male WT and Washc1ΔHep mice (n = 6–7). (D) Fractional catabolic rate of plasma HDL holopar-
ticle (125I), HDL-C (3H), and selective HDL-C clearance (3H–125I) of male WT and Washc1ΔHep mice. (E) HDL holoparticle (125I), 
HDL-C (3H), and selective HDL cholesterol uptake (3H–125I) in liver of male WT and Washc1ΔHep mice (n = 6–7). Data are 
presented as the mean ± SEM, *P < 0.05, **P < 0.01, as determined by Student’s t test.
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levels of  LDLR were assessed by immunoblot analysis. As shown in Figure 7, D and E, loss of  WASHC1 
accelerated IDOL-mediated LDLR degradation. Taken together, these results suggest that the WASH com-
plex participates in the IDOL-LDLR degradation pathway but not in the PCSK9-LDLR axis.
Discussion
Mutations in subunits of  the WASH complex have been correlated with developmental and neurologi-
cal defects in humans (12, 14, 15, 48). Here, we report that the WASH complex also has a pivotal role in 
the maintenance of  plasma cholesterol levels. Our data indicate that WASH orchestrates the trafficking 
of  the lipoprotein receptors LDLR and LRP1 as well as SR-BI to the plasma membrane for hepatic 
clearance of  LDL-C and HDL-C, respectively.
The endolysosomal system consists of a series of organelles that is required to maintain cellular cholesterol 
and lipid homeostasis (49). In this article, we show that the WASH complex is also essential for the archi-
tecture of the endolysosomal system in hepatocytes, which is in line with previous observations in MEFs (4, 
8–10). LDL-C bound to LDLR is hydrolyzed in the late endosomes/lysosomes (LEs/LYs) and, subsequently, 
exported from LEs/LYs by Niemann-Pick disease type C (NPC) proteins to the plasma membrane or endo-
plasmic reticulum (49). Loss of NPC impairs cholesterol export and enhances SREBP-2 activity, resulting in 
increased cholesterol biosynthesis and LDLR-mediated uptake and, eventually, in cholesterol accumulation in 
LEs/LYs (50, 51). Here, we found that the disturbed endolysosomal architecture in Washc1ΔHep mice does not 
cause a defective intracellular cholesterol transport, considering that the protein levels of NPC1 (data not shown) 
and SREBP-2 activity were not changed upon Washc1 ablation. In line with these findings, hepatic cholesterol 
Figure 6. Characterization of Washc1/Commd1ΔHep mice. (A) WASHC1 and COMMD1 protein levels in livers of male Washc1/Commd1ΔHep and WT mice as 
determined by immunoblotting. (B) Total plasma cholesterol of male Washc1ΔHep, Commd1ΔHep, and Washc1/Commd1ΔHep mice and their littermate controls 
(WT) (n = 6–9). (C) Plasma apolipoprotein levels in male WT and Washc1/Commd1ΔHep mice determined by targeted proteomics, indicated by fold change vs 
WT littermate controls (n = 6–8). (D) Cholesterol levels of FPLC fractionated plasma pools of the experimental groups of mice. (E) Apolipoprotein levels in 
pooled FPLC fractionated plasma depicted in D as determined by targeted proteomics, indicated as percentage relative to the total apolipoprotein levels in 
these fractions. BLD, below detection limit. Data are presented as the mean ± SEM, ***P < 0.001 as determined by Student’s t test.
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content and hepatic cholesterol synthesis were not affected by WASH deficiency. Although hepatic LXR activity 
was slightly reduced upon Washc1 ablation, this change did not translate into aberrant hepatic bile acid synthesis 
or biliary cholesterol and bile acid excretion during the investigation. Importantly, fecal neutral sterol and bile 
acid loss were unaffected in WASHC1-deficient mice, indicating unaffected whole-body cholesterol turnover. 
The lysosome is also an essential organelle in autophagy, a catabolic process important in maintaining hepatic 
and plasma TG levels and hepatic fatty acid oxidation (52). Interestingly, it has been shown that WASHC1 
inhibits autophagic flux during mouse embryogenesis (53), but under the tested conditions, plasma and hepatic 
TG were not affected in hepatic WASHC1-deficient mice. Altogether, our data provide no evidence that hepatic 
WASHC1 deficiency results in dysfunctional lysosomes and aberrant intracellular cholesterol transport or cho-
lesterol synthesis, despite their abnormal architecture.
In agreement with our in vitro studies (16), hepatocyte-specific WASH deficiency leads to reduced 
LDLR and LRP1 levels in the plasma membrane, which likely underlies elevated plasma LDL-C levels 
in Washc1ΔHep mice. Interestingly, however, we also found an increase in HDL-C in Washc1ΔHep mice. 
The diminished surface levels of  SR-BI accompanied by reduced selective hepatic HDL-CE uptake sug-
gest that the functioning of  SR-BI—the main receptor for hepatic HDL-C uptake in mice (54, 55)—is 
dependent on the WASH complex. The importance of  hepatic SR-BI for HDL-C metabolism has also 
been shown in humans (56). Individuals who are heterozygous for a loss-of-function variant in SCARB1 
(P376L), the gene encoding SR-BI, have increased levels of  plasma HDL-C (56). Furthermore, common 
genetic variants near SCARB1 have been found to be correlated with plasma HDL-C levels (57, 58), 
underlying the importance of  SR-BI in HDL-C metabolism in both species.
Figure 7. WASH deficiency increases IDOL-mediated LDLR degradation but did not affect the proteolysis of LDLR by PCSK9. (A) WASHC1 levels in WT 
and Washc1-knockout MEFs, as determined by immunoblotting. (B) MEFs were cultured in sterol-depleted medium for 24 hours and then incubated with 
recombinant human PCSK9 (2.5 mg/ml) for the indicated times. In the immunoblot analysis of LDLR, the blots represent 3 independent experiments. (C) 
Quantification of the time course of PCSK9-mediated LDLR degradation as shown in (B) (n = 3). (D) MEFs were cultured in sterol-depleted medium for 24 
hours prior to T09 (1 μM) incubation for the indicated times. Total LDLR protein levels were determined by immunoblot analysis, and the blots represent 
3 independent experiments. (E) Quantification of LDLR levels relative to time point 0 hours (n = 3); the representative picture is shown in D. Data are 
presented as the mean ± SEM, ***P < 0.001 as determined by Student’s t test. 
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Notably, in addition to increased plasma LDL-C levels, plasma HDL-C levels were also reported to 
be relatively high in a patient with RSS with a homozygous hypomorphic WASHC5 allele (16). Similar to 
the patient with RSS, both LDL-C and HDL-C are elevated in patients with X-linked intellectual disability 
caused by mutations in the gene encoding the CCC-complex component CCDC22 (16). Our current and 
previous mouse models mimic the dyslipidemic phenotype of  patients with RSS and those with X-linked 
intellectual disability, as plasma LDL-C and HDL-C levels are both elevated upon either WASH or CCC 
ablation in mouse livers (16, 17), suggesting that both the CCC and WASH complexes are required for effi-
cient hepatic LDL-C and HDL-C uptake in men and mice.
In vitro studies have shown that the CCC complex is physically associated with the WASH complex 
through the binding of  the CCC components CCDC93 and CCDC22 to the WASH subunit WASHC2 
(FAM21) (5). This interaction is required for the localization of  the CCC complex to endosomes and 
subsequently for endosomal trafficking of  integral membrane proteins. Furthermore, we have shown 
that loss of  the CCC complex leads to increased expression of  several WASH subunits, including 
WASHC1 (17). Here, we provide genetic evidence that the WASH and CCC complexes act in concert 
in the endosomal cargo recycling pathway, as inactivation of  both complexes in mouse livers does not 
exacerbate the hypercholesterolemic phenotype.
The findings of  our current study are particularly important, as very little is known about the mechanisms 
by which the endosomal trafficking of  SR-BI is regulated. Several studies have shown that SR-BI is endocyto-
sed (59, 60) and localized in recycling endosomes (60). Our results indicate that the localization of  SR-BI at 
the plasma membrane largely relies on the WASH-CCC axis. Based on the role of  the WASH-CCC pathway 
in endosomal cargo recycling, we hypothesize that, after internalization, SR-BI is further transported to the 
endosomes from where it is directed back to the plasma membrane. The function of  SR-BI being endocytosed 
and recycled is still unclear, as the selective uptake of  HDL-CE by SR-BI is independent of  the endocytosis 
of  the entire HDL particle or SR-BI (44, 61, 62). Similar observations were made in this study, in which an 
impairment of  the WASH-CCC axis only led to reduced HDL-CE uptake without affecting ApoA-I clearance 
as well as its plasma levels, as expected in case of  a reduction in the amount of  SR-BI at the cell surface. It 
has been suggested, however, that SR-BI recycling might be involved in the retroendocytosis of  HDL and 
facilitates transcytosis and transport of  HDL-C into the bile canaliculus (60). Yet, we did not find any chang-
es in biliary cholesterol excretion, which may suggest that a compensatory adaptive response is induced. It 
may well be that more significant conditions (e.g., blocking of  endogenous cholesterol synthesis) are required 
to unmask a phenotype in this respect. Thus, our results and model might thus be relevant to obtain better 
insights into the biology of  the intracellular trafficking pathway of  SR-BI in cholesterol homeostasis.
The endolysosomal system is fundamental for the PCSK9- and IDOL-mediated degradation pathways 
(18–22). Here, we demonstrate that impaired endosomal LDLR recycling by the loss of WASHC1 does not 
affect PCSK9-mediated LDLR degradation. However, WASHC1 deficiency does accelerate LDLR proteolysis 
promoted by IDOL. These data indicate that the itinerary of PCSK9-LDLR to the lysosome is spatially sepa-
rated from the LDLR recycling route (11, 23, 63). On the other hand, LDLR targeted by IDOL for proteolysis 
might be transported to WASH-positive endosomes from where LDLR is further transported to the lysosome 
for degradation. Of note, it has been shown that endosomal sorting complexes required for transport machin-
ery (ESCRT) is required for IDOL-mediated LDLR degradation (19, 20, 22), and it has been proposed that 
ESCRT facilitates the transport of receptors into the lysosome that are not retrieved and, subsequently, recycled 
by the WASH-CCC axis (11, 23, 63). Altogether, these data imply that the WASH complex participates in the 
sorting of ubiquitylated LDLR by IDOL to the lysosome.
Our data also unexpectedly suggest that overexpression of  PCSK9 lowers hepatic LRP1 levels in 
Washc1ΔHep mice. It has been shown that PCSK9 can bind to and decrease LRP1 in different cell lines 
(64). However, we and others could not confirm a role for PCSK9 in hepatic LRP1 degradation in WT 
mice, nor in hepatic COMMD1-deficient mice (17, 37, 38). The underlying mechanism explaining our 
observation is unclear, but it has been speculated that the mammalian ATP-binding cassette transporter 
ABCA7 may have a role in stabilizing LRP1. ABCA7 is highly expressed in the liver (64), and it might 
be that disruption of  the WASH complex impairs the protective function of  ABCA7 in the stabilization 
of  LRP1 and, hereby, sensitizes LRP1 for PCSK9-mediated degradation. Future experiments are need-
ed to understand this observation at a molecular level.
In conclusion, this study extends the mechanistic basis for the increased plasma cholesterol levels in 
humans with defects in the WASH-CCC axis and appeal for extra medical attention with regard to plasma 
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lipid levels and atherosclerotic cardiovascular disease risk. In addition, our work provides insights in the 
role of  the WASH complex in IDOL- and PCSK9-mediated LDLR degradation.
Methods
Animals. Washc1f/f C57BL/6 mice (4) were crossed with Alb-Cre–expressing mice (The Jackson Laboratory, 
stock 003574) to generate liver-specific Washc1-knockout mice. The mice studied were between 12 and 20 weeks 
of age, and male mice were predominantly used for this study (except for the data shown in Supplemental 
Figure 2). The following primers were used for genotyping of the mice: floxed Washc1 forward (5′-CGCATT-
GATCTTCCTATACGC-3′) and reverse (3′-TGTCAGTCCTATGCTTAGTG-5′), Alb-Cre forward (5′-GCG-
GTCTGGCAGTAAAAACTATC-3′), and reverse (5′-ACGAACCTGGTCGAAATCAGTG-3′). The liver-spe-
cific Commd1-knockout mice have been generated as described previously (46). Mice lacking both COMMD1 
and WASHC1 in the liver were obtained by intercrossing liver-specific Commd1- and Washc1-knockout mice.
To ablate hepatic LDLR expression of  Washc1ΔHep mice and WT littermates, we expressed PCSK9-D377Y 
in the liver of  these mice by retro-orbital injection of  3.0 × 1011 vector genomes of  AAV-PCSK9-D377Y, per-
formed similar to that previously described (17). CETP expression was induced by injection of  5.0 × 1011 
Ad-CETP particles via the orbital vein adjusted to 100 μl with sterile PBS. Ad-CETP virus was provided 
by Uwe Tietge (Department of  Pediatrics, University of  Groningen, University Medical Center Groningen, 
Groningen, the Netherlands).
All experiments have been performed with male mice (n = 4–7). Mice were housed individually and fed 
ad libitum with a standard rodent chow diet (RMH-B, AB Diets, the Netherlands). In all experiments, litter-
mates were used as WT controls. Before sacrifice, mice were fasted for 4 hours. Tissues for mRNA and pro-
tein expression analysis were snap frozen in liquid nitrogen and stored at –80°C until further analysis. Blood 
was drawn by cardiac puncture, and plasma was collected after centrifugation at 1,000 g for 10 minutes at 4°C.
Tissue culture. WT and WASHC1-deficient mouse embryonic fibroblasts were cultured as described 
previously (16). Prior to PCSK9 (PC9-H5223, ACRO Biosystems) incubation (2.5 μg/ml), the MEFs were 
cultured in DMEM GlutaMAX with 2% LPDS for 24 hours. MEFs were cultured for 24 hours in DMEM 
GlutaMAX supplemented with 2% lipoprotein-deficient serum, 100 μM mevalonate, and 5 μg/ml of  sim-
vastatin before the LXR agonist T0901317 (T2320, MilliporeSigma) (1 μM) was added to the media. Cells 
were harvested at the indicated time points for immunoblotting.
Immunoblotting. For immunoblotting, liver homogenates were obtained using NP40 buffer (0.1% Nonidet 
P-40 [NP-40], 0.4 M NaCl, 10 mM Tris-HCl [pH 8.0], 1 mM EDTA) supplemented with protease and phos-
phatase inhibitors (Roche). Protein concentration was determined using the Bradford assay (Bio-Rad). Thir-
ty micrograms of  protein was separated using SDS-PAGE and transferred to Amersham Hybond-P PVDF 
Transfer Membrane (GE Healthcare; RPN303F). Membranes were blocked in 5% milk in Tris-buffered saline 
with 0.01% Tween 20 (MilliporeSigma) and incubated with the indicated antibodies. Proteins were visualized 
using a ChemiDoc XRS + System using Image Lab software version 5.2.1 (both from Bio-Rad).
Antibodies. A list of  commercially bought antibodies is provided in Supplemental Table S2. Rabbit poly-
clonal antibodies against WASH1 (1:1000) (9), FAM21 (1:100) (9), CCDC53 (WASHC3, 1:1000) (65) and 
Strumpellin (WASHC5, 1:1000) (65) were previously described.
Transmission EM sample preparation and analysis. For EM analysis, mice were fasted for 18 hours and perfu-
sion fixed with 4% formaldehyde in 0.1 M phosphate buffer. The livers from the animals were rapidly removed, 
cut into small pieces (~2 mm3), and placed and stored in glass vials with 4% formaldehyde until further pro-
cessed. Samples were fixed at room temperature by adding Karnovsky fixative (2.5% glutaraldehyde and 2% 
formaldehyde (Electron Microscopy Sciences) in 0.2 M Cacodylate buffer, pH 7.4) for 2 hours at room tempera-
ture. They were then postfixed with 1% OsO4/1.5% K3Fe(III)(CN)6 in 0.065 M phosphate buffer for 2 hours 
at 4°C and finally for 1 hour with 0.5% uranyl acetate. After fixation, samples were dehydrated and embedded 
in Epon epoxy resin (Polysciences). Sixty-nanometer ultrathin sections were made and contrasted with uranyl 
acetate and lead citrate using the AC20 (Leica) and examined with a Technai T12 electron microscope (FEI 
Thermo Fischer). Images were taken from 2 different blocks per mouse and per condition. Twenty-five random 
images per block were collected for each mouse per condition (100 random images per condition).
All measurements on the lysosome size were taken using FiJi software. For the quantification of  the 
lysosome area, the perimeters of  lysosomes were selected one by one using the freehand selection tool in 
FiJi, and the encircled area was measured. For visualization of  lysosomal tubulation, lysosomal perimeters 
were selected using the Lasso tool in Adobe Photoshop and the selected organelles were colored.
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FPLC. Plasma samples of  each group of  mice were pooled and fractionated by FPLC as previously 
described (66), with minor modifications. In brief, the system contained a PU-980 ternary pump with an 
LG-980-02 linear degasser and a UV-975 UV/VIS detector (Jasco). EDTA plasma was diluted 1:1 with 
Tris-buffered saline, and 300 μl sample/buffer mixture was loaded onto a Superose 6 HR 10/300 column 
(GE Healthcare, Life Sciences Division) for lipoprotein separation at a flow rate of  0.5 ml/min. TC and 
TG content of  the fractions was determined as described in the information to follow.
Hepatic lipid extraction. Liver homogenates prepared as 15% (w/v) solutions in PBS were subjected to 
lipid extraction according to the Bligh & Dyer method (67). In short, 600 ml of  demi-water was mixed with 
200 ml of  liver homogenate and 3 ml of  chloroform. After 30 minutes of  incubation, 1.2 ml of  H2O and 1 
ml of  chloroform were added, mixed, and subsequently centrifuged (10 min, 500 g at room temperature). 
The chloroform layer was transferred into a new glass tube and was evaporated using nitrogen at 50°C. Lip-
ids were resolved in 1 ml of  chloroform and used for further determination of  cholesterol and TG content.
Cholesterol and TG analysis in plasma and liver. TC levels were determined using colorimetric assays 
(11489232, Roche) with cholesterol standard FS (DiaSys Diagnostic Systems GmbH) as a reference. 
TG levels were measured using a Trig/GB kit (1187771, Roche) with Roche Precimat Glycerol standard 
(16658800) as a reference.
Targeted liquid chromatography-mass spectrometry analysis. To quantify the protein concentrations of  
ApoA1, ApoB, and ApoE in mouse plasma, we used a targeted proteomics assay as previously described 
(17). The protein levels of  HL in nonheparinized plasma were quantified using the isotopically labeled stan-
dard peptide LSPDDANFVDAIHTFTR. Isotopically labeled standards were generated by concatenating 
all target peptides into synthetic proteins (Polyquant GmbH) containing 13C-labeled lysines and arginines 
(so-called QconCATs). The known concentrations of  these standard peptides were used to calculate the 
concentrations of  the endogenous equivalents of  the peptides (in amount of  protein [μg or mg] per volume 
[dl] plasma or FPLC fraction).
In-gel digestion and liquid chromatography-mass spectrometry (LC-MS) analyses were performed as 
described previously (17) with the following alterations: For plasma samples, 1 μl plasma plus 20 ng Qcon-
CATs were loaded on the gel, and an equivalent of  100 nl plasma plus 2 ng QconCATs was injected in the 
LC-MS for analysis.
For the FPLC fractions, 15 μl of  the pooled FPLC fractions was loaded on the gel. The QconCATs 
were mixed after digestion, and the cleanup step after the digestion was excluded. An equivalent of  a 3-μl 
sample plus 0.4 to 1 ng QconCATs was injected in the LC-MS for analysis.
Gene expression analysis. One hundred milligrams of mouse liver was homogenized in 1 ml QIAzol Lysis 
Reagent (Qiagen). Total RNA was isolated by chloroform extraction. Isopropanol-precipitated and etha-
nol-washed RNA pellets were dissolved in RNase/DNase-free water. One microgram of RNA was used to 
prepare cDNA with the Transcriptor Universal cDNA Master kit (Roche), according to the manufacturer’s 
protocol. Twenty nanograms of cDNA was used for quantitative real-time PCR (qRT-PCR) analysis using the 
FastStart SYBR Green Master (Roche) and the 7900HT Fast Real-Time PCR System (Applied Biosystems). 
The PCR reaction was performed as follows: 2 minutes at 50°C, 10 minutes at 95°C, 40 cycles of 15 seconds 
at 95°C, and 1 minute at 60°C. Expression data were analyzed using SDS 2.3 software (Applied Biosystems), 
using the ΔΔCT method of calculation. PPIA expression was used as an internal control. The sequence of the 
primers is available upon request.
Biotinylation assay. Culture of  primary hepatocytes and biotinylation assay were performed as previ-
ously described (38). Cells were washed 3 times with ice-cold PBS-CM buffer (PBS, 1-mM MgCl2, and 
0.1 mM CaCl2). Subsequently, 0.5 mg/ml biotin reagent solution (EZ-Link Sulfo-NHS-SS Biotin, Ther-
mo Scientific) in biotinylation buffer (10 mM triethanolamine, pH 8.0, 150 mM NaCl, and 2 mM CaCl2) 
was added to the cells for 30 minutes at 4°C. The biotin reagent was removed, and cells were washed 
once with quenching buffer (PBS-CM, 25 mM Tris-HCl, pH 7.4, and 192 mM glycine) for 30 minutes 
at 4°C. Next, cells were washed twice with PBS-CM and once with TBS-C (50 mM Tris-Cl, pH 7.4, 100 
mM NaCl, and 2 mM CaCl2). Cells were collected by scraping in TBS-C. Cells were centrifuged (1,000 
g, 5 min, 4°C), lysed in biotin lysis buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodi-
um deoxycholate, 5 mM EDTA, and 5 mM EGTA), incubated on ice for 15 minutes, and subsequently 
centrifuged for 15 minutes at 12,000 g. Protein concentration was determined: 30 mg was used as input, 
300 mg was used diluted in biotin lysis buffer (500 μl), and 30 μl Neutravidin beads (Neutravidin plus 
ultralink beads, Thermo Scientific) were added and incubated for 4 hours at 4°C. Beads were collected by 
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centrifugation (500 g, 5 min), washed 3 times with Biotin lysis buffer, once with high-salt buffer (50 mM 
Tris-Cl, pH 7.4 and 500 mM NaCl), and once with low-salt buffer (10 mM Tris-HCl). Finally, the beads 
were resuspended in 30 μl 2× loading buffer.
Radioactive labeling of  HDL. Total human HDL (1.063 <d <1.21 g/ml) was obtained by sequential 
ultracentrifugation as described before (68). HDL was labeled with 125I by a modification of  the iodine 
monochloride method (69). To label HDL with 3H-cholesteryl-ether (3H-CE), 500 μCi of  3H-CE resus-
pended in 50 μl of  ethanol was added to a solution containing heat-inactivated human lipoprotein-deficient 
serum (200 mg protein) and iodinated HDL (6 mg protein). Radiolabeled HDL was incubated overnight 
at 37°C with gentle shaking, followed by re-isolation of  the labeled HDL by sequential ultracentrifugation. 
Animals were injected with 8333 Bq 3H-CE with an activity of  357 Bq/μg HDL and 33333Bq 125I-HDL 
with an activity of  2465 Bq/μg HDL.
VLDL production assay. After a 4-hour morning fasting, mice were injected i.p. with 100 mg/ml polox-
amer 407 (BASF) in PBS (1 g per kg body weight). Blood was drawn by retro-orbital puncture at time points 
0, 30, 60, 120, and 240 minutes. Plasma samples were used for TG determination.
Determination of  cholesterol synthesis in vivo. [13C]-acetate was added to drinking water (99 atom %, 
Isotec/MilliporeSigma) for 3 days. Every 12 hours, a blood sample was taken via tail bleeding on filter 
paper to determine fractional cholesterol synthesis rates. Total cholesterol (TC) was extracted from blood 
spots using ethanol/acetone (1:1 v/v). Cholesterol synthesis measurements were performed as previously 
described (70).
Fecal and biliary bile acid and cholesterol measurements. Feces were collected over a period of 24 hours. Mice 
were anesthetized by i.p. injection of Hypnorm (1 ml/kg) (fentanylcitrate 0.315 mg/ml and fluanisone 10 mg/
ml, VetaPharma) and diazepam (10 mg/kg) (Centrafarm) and subjected to gallbladder cannulation for 20 min-
utes as described previously (71). During bile collection, body temperature was stabilized using an incubator. 
Bile was stored at −20°C until analyzed. Cholesterol and bile acids were measured as described earlier (72, 73).
Statistics. In vitro data were obtained from 3 independent experiments ± SEM. Mouse data show aver-
age values ± SEM (n = 4–7). Analyses were performed using GraphPad version 6.05 (GraphPad software). 
Unpaired 2-tailed Student’s t test was used to test for statistical significance between 2 groups. For all exper-
iments, a P value of  < 0.05 was considered statistically significant.
Study approval. All animal studies were approved by the Institutional Animal Care and Use Committee, 
University of  Groningen (Groningen, the Netherlands).
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